Therapeutic uses of anti-interleukin-6 receptor antibody (Q38241714)

31 August 2017

title

Therapeutic uses of anti-interleukin-6 receptor antibody (English)

1 reference

31 August 2017

0 references

1 reference

Sujin Kang

1 reference

31 August 2017

Toshio Tanaka

series ordinal

1 reference

31 August 2017

Tadamitsu Kishimoto

series ordinal

1 reference

31 August 2017

publication date

20 August 2014

1 reference

31 August 2017

published in

International Immunology

1 reference

31 August 2017

1 reference

31 August 2017

1 reference

31 August 2017

page(s)

21-29

1 reference

Pleiotropy and redundancy: T cell-derived lymphokines in the immune response

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Molecular regulation of B lymphocyte response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Interleukin-6 and its receptor: a paradigm for cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Impaired immune and acute-phase responses in interleukin-6-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Interleukin-6: from basic science to medicine--40 years in immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Therapeutic targeting of the interleukin-6 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

IL-6: regulator of Treg/Th17 balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

The origins, function, and regulation of T follicular helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Haemopoietic receptors and helical cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Molecular cloning and expression of an IL-6 signal transducer, gp130

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Cytokine signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Gp130 and the interleukin-6 family of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Structure and function of a new STAT-induced STAT inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Specific Inhibition of Stat3 Signal Transduction by PIAS3

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

The roles of aryl hydrocarbon receptor in immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Aryl hydrocarbon receptor deficiency in T cells suppresses the development of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Post-transcriptional control of cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

The biology and medical implications of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU081

21 January 2018

Identifiers

DOI

10.1093/INTIMM/DXU081

1 reference

31 August 2017

1 reference